Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer’s disease

Conclusions: The primary outcome of this trial was negative. The data suggest that bexarotene reduced brain amyloid and increased serum Aβ 1–42 in ApoE4 noncarriers. Elevated triglycerides could represent a cardiovascular risk, and bexarotene should not be administered outside a research setting. RXR agonists warrant further investigations as AD therapies.Trial registrationClinicalTrials.gov identifier NCT01782742. Registered 29 January 2013.
Source: Epidemiologic Perspectives and Innovations - Category: Epidemiology Authors: Source Type: research